Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 300

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Status: Active
Location: 4 locations
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Lurbinectedin in Combination with Paclitaxel and Bevacizumab for the Treatment of Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancers
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
CPI-0209 in Combination with Carboplatin for the Treatment of Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Status: Active
Location: 2 locations
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Hyperthermic Intraperitoneal Chemotherapy with Cisplatin After Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
Cirtuvivint and Olaparib for the Treatment of Patients with BRCA/HRD Platinum Resistant Ovarian Cancer
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Autologous B7-H3 Chimeric Antigen Receptor T Cells for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T cells for the Treatment of Patients with Recurrent Platinum Resistant or Refractory Epithelial Ovarian Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas